|
gptkbp:instanceOf
|
gptkb:company
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Reshma_Kewalramani
|
|
gptkbp:collaboratesWith
|
gptkb:Moderna
gptkb:CRISPR_Therapeutics
|
|
gptkbp:CUSIP
|
92532F100
|
|
gptkbp:focus
|
cystic fibrosis treatments
|
|
gptkbp:foundedYear
|
1989
|
|
gptkbp:founder
|
gptkb:Joshua_Boger
|
|
gptkbp:headquartersLocation
|
gptkb:Boston,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
VRTX
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US92532F1003
|
|
gptkbp:marketCap
|
over $100 billion (2024)
|
|
gptkbp:memberOf
|
gptkb:NASDAQ-100
gptkb:S&P_500
|
|
gptkbp:name
|
gptkb:Vertex_Pharmaceuticals_Incorporated
|
|
gptkbp:numberOfEmployees
|
about 4,500
|
|
gptkbp:product
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Symdeko
gptkb:Trikafta
|
|
gptkbp:researchInterest
|
gene editing
rare diseases
|
|
gptkbp:SIC
|
2836
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:S&P_500
gptkb:NASDAQ_Biotechnology_Index
|
|
gptkbp:stockSymbol
|
gptkb:VRTX
|
|
gptkbp:website
|
https://www.vrtx.com/
|
|
gptkbp:bfsParent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|